President Donald Trump rescinded an executive order issued by former President Joe Biden aimed at finding new models for lowering drug costs. Trump's action didn't affect the caps on seniors' drug costs or Medicare price negotiations that Biden signed into law.

January, the Biden administration released its proposed Medicare Advantage rates in 2026. These are the rates that the government pays insurers for the program to provide low-cost, affordable plans for seniors.

“Today, I’m proud to announce that my Administration has selected the next 15 drugs for Medicare drug price negotiation. The drugs treat conditions such as diabetes and cancer, and seniors across the country rely on them,” President Joe Biden said in ...

A provision about insulin in the Inflation Reduction Act is conflated with a 2022 executive order by former President Joe Biden on lowering prescription drug costs in posts online that suggest President Donald Trump has canceled the $35 insulin co-pay cap for certain Medicare programs.

to develop and test ways to lower drug prices for people on Medicare and Medicaid. Since former-President Joe Biden's 2022 order, CMS had been planning out and preparing to test three models to lower prices. None of them had fully gone into effect.

“Rescinding the cap on insulin at $35 only makes pharmaceutical richer and everyday Americans, including MAGA voters, seriously poorer,” Steven Bechloss—author of the Substack, America, America — posted to the Bluesky social media platform.

Donald Trump has rescinded an executive order from President Joe Biden that sought to lower the price of drugs.

Trump stopped a program that had been in the works and was intended to give Medicare recipients access to more than 100 generic drugs for $2 a month, according to another executive order signed on Trump's first day in his new term.

The executive order, which Biden signed in October 2022, had not spurred any lower drug prices by the time Trump revoked it Jan. 20. The order directed the Health and Human Services Department secretary to consider "new health care payment and delivery models" for the Center for Medicare and Medicaid Innovation to test.

Experts suggest that most Americans will not experience immediate changes in their out-of-pocket health care expenses.

President Trump is rolling back Biden healthcare policies, such as expansions to the Affordable Care Act – a move Democrats described as an "attack" on the federal program.

The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower prescription costs — is befuddling drug pricing experts.